Search

Your search keyword '"Alonso-Orduna, V."' showing total 32 results
Start Over Author "Alonso-Orduna, V."
32 results on '"Alonso-Orduna, V."'

1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

Author

Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., and Aranda, E.

Published
2023
Full Text
View/download PDF

3. 378P Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study

Author

Vidal Barrull, J., primary, Nieva Munoz, M., additional, Fernandez-Rodriguez, C., additional, García Alfonso, P., additional, Paez, D., additional, Alonso-Orduna, V., additional, Cano Osuna, M.T., additional, Santos Vivas, C., additional, Duran, G., additional, Elez Fernandez, M.E., additional, Manzano Mozo, J.L., additional, Garcia-Carbonero, R., additional, Pineda, E., additional, Sastre Varela, J., additional, Rivera Herrero, F., additional, Bellosillo Paricio, B., additional, Tabernero, J., additional, Aranda Aguilar, E., additional, Salazar, R., additional, and Montagut Viladot, C., additional

Published
2022
Full Text
View/download PDF

4. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Author

Andel, J., Balcke, P., Benedicic, B., Eisterer, W., Fridrik, M., Jagdt, B., Keil, F., Kretschmer, A., Krippl, P., Oexle, H., Pecherstorfer, M., Samonigg, H., Schmid, M., Thaler, J., Tinchon, C., Weiss, H., Arts, J., De Man, M., Demolin, G., Janssens, J., Polus, M., Benczikova, B., Melichar, B., Prausova, J., Vitek, P., Andersen, F.Z., Jensen, B.B., Keldsen, N., Østerlind, K., Vistisen, K., Elme, A., Magi, A., Ojamaa, K., Ristamäki, R., Salminen, T., Ben Abdelghani, M., Bouche, O., Borg, C., Bouhier-Leporrier, K., Breysacher, G., Chone, L., Clavero Fabri, M.-C., Deplanque, G., Desseigne, F., Dourthe, L.-M., Ezenfis, J., Faroux, R., François, E., Garnier, C., Gaspard, M.-H., Hebbar, M., Illory, J.F., Kaminsky, M.-C., Lecomte, T., Legoux, J.-L., Levache, B., Lobry, C., Lotz, J.-P., Mabro, M., Manet-Lacombe, S., Manfredi, S., Matysiak Budnik, T., Miglianico, L., Mineur, L., Moullet, I., Naman, H., Nouyrigat, P., Oziel-Taieb, S., Perrier, H., Pezet, D., Philip, J., Pottier, V., Porneuf, M., Ramdani, M., Re, D., Rinaldi, Y., Spaeth, D., Taieb, J., Terrebonne, E., Texereau, P., Thirot Bidault, A., Tournigand, C., Tubiana-Mathieu, N., Vantelon, J.-M., Viret, F., Ychou, M., Bangerter, M., Bertram, M.E., Bohnsteen, B., Brinkmann, L., Caca, K., Constantin, C., Cordes, H.-J., Dietrich, G., Eggert, J., Engel, E., Fahlke, J., Fensterer, H., Florschütz, A., Folprecht, G., Forstbauer, H., Freier, W., Freund, M., Frickhofen, N., Gäbele, E., Geißler, M., Gieseler, F., Göhler, T., Graeven, U., Groschek, M., Grundeis, M., Hacker, U., Hagen, V., Hebart, H.F., Hegewisch-Becker, S., Heike, M., Herrmann, T., Hildebrandt, B., Höffkes, H.-G., Hübner, G., Hübner, J., Kettner, E., Kneba, M., Kohnke, J.W., Kojouharoff, G., König, C., Kretzschmar, A., Kröning, H., Kürner, K., Lammert, F., Lerchenmüller, C., Lück, A., Meiler, J., Mergenthaler, H.-G., Müller, L., Müller-Naendrup, C., Nusch, A., Papke, J., Porschen, R., Rädle, J., Reddemann, C., Ridwelski, K., Riera-Knorrenschild, J., Rudi, J., Schmalenberger, A., Schimanski, C.-C., Schlegel, F., Schlichting, C., Schmidt, P., Schmiegel, W., Schmitz, S., Schulze-Bergkamen, H., Schwaner, I., Schwarzer, A., Schwerdtfeger, M., Selbach, J., Sieber, M., Siebler, J., Staib, P., Stauch, M., Steffens, C.-C., Stübs, P., Tischendorf, J., Trarbach, T., Tummes, D., Valdix, A.-R., Vogel, A., Von Wichert, G.P.L., Walther, M., Welslau, W., Wilhelm, G., Wobster, H., Wolf, T., Zeigenhagen, N., Zomorodbaksch, B., Batman, E., Bloemendal, H.J., Kehrer, D.F.S., Guren, T., Indrebø, G., Kersten, C., Soerbye, H., Fragoso, M., Fragoso, R., Mellidez, J.C., Sa, A., Aljobran, A., Darwish, T., Alonso-Orduna, V., Aparicio, J., Aranda, E., Bosch, C., Galan-Brotons, A., Busquier Hernandez, I., Camara, J.C., Campos Cervera, J.M., Carlos Garcia Giron, C., Del Prado, P.M., Donnay, O., Escudero, P., Falco, E., Gallego Plazas, J., Garcia Alfonso, P., Gonzalez Flores, E., Gravalos, C., Guardeno, R., Juárez, A., Lopez Ladron, A., Losa Gaspa, F., MªVicent Vergé, J., Marcuello Gaspar, E., Massuti Sureda, B., Molina, J., Montero, I.C., Muñoa, A.L., Naranjo, M.B., Oruezabal Moreno, M.J., Pachón Olmos, V., Pericay, C., Reina Zoilo, J.J., Rivera, F., Ruiz Casado, A., Safont, M.J., Salud Salvia, A., Tobena, M., Toral, J.C., Valenti, V., Valladares Ayerbes, M., Vieitez, J.M., Vera, R., Berglund, A., Fernebro, E., Hess-Umbricht, V., Pless, M., Popescu, R., Winterhalder, R., Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., and Arnold, D.

Published
2013
Full Text
View/download PDF

5. 588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study

Author

Martelli, V., Barrull, J. Vidal, Rodriguez, C. Fernandez, Toledo, R.D.A., Gibert, J., Alfonso, P. García, Paez, D., Alonso-Orduna, V., Gomez España, M.A., Vivas, C. Santos, Ogaya, G. Duran, Fernandez, M.E. Elez, Garcia-Carbonero, R., Monteagudo, R. Ferreiro, Mozo, J.L. Manzano, Paricio, B. Bellosillo, Tabernero, J., Soler, R. Salazar, Aguilar, E. Aranda, and Viladot, C. Montagut

Published
2024
Full Text
View/download PDF

6. 511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial

Author

Vivas, C. Santos, Barrull, J. Vidal, Rodriguez, C. Fernandez, Ballabrera, F. Salvà, Alonso-Orduna, V., Garcia-Carbonero, R., Losa, F., Llavero, N. Tarazona, Aguileria, M.J. Safont, Herrero, F. Rivera, Romero, L. Layos, Morales, M.J. Ortiz, Salud, A., Alcaide-Garcia, J., Paez, D., Hernandez-Yagüe, X., Gallego, R. Alvarez, Vera, R., Paricio, B. Bellosillo, and Viladot, C. Montagut

Published
2024
Full Text
View/download PDF

7. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Author

Calvo-Lopez T, Paz-Cabezas M, Llovet P, Ibanez M, Sastre J, Alonso-Orduna V, Vieitez J, Yubero A, Vera R, Asensio-Martinez E, Garcia-Alfonso P, Aranda E, Diaz-Rubio E, and Perez-Villamil B

Subjects
stage III, microsatellite instability, microRNAs expression, Colorectal cancer, survival, prognostic biomarkers
Abstract

BACKGROUND: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors. OBJECTIVE: To confirm in stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease. To correlate miR expression with microsatellite instability (MSI) and mutations in RAS and BRAF. METHODS: miR-21, miR-135a, miR-206, miR-335 and miR-Let-7a expression was analyzed by RT-qPCR in 150 patients out of the 329 patients used to analyze MSI and RAS and BRAF mutations. Association with disease free survival (DFS) and overall survival (OS) was analyzed. Data was confirmed by a multivariate analysis. RESULTS: MiR-21 high expression ( p = 0.034) and miR-335 low expression ( p = 0.0061) were significantly associated with MSI-H. A positive trend (p = 0.0624) between miR-135a high expression and RAS mutations was found. Lower miR-21 expression levels are associated with DFS (HR = 2.654, 95% CI: 1.066-6.605, p = 0.036) and a trend with OS (HR = 2.419, 95% CI: 0.749-7.815, p = 0.140). MiR-21 high expression significantly improves DFS of the poor prognosis group (T4 or N2) (p = 0.03). CONCLUSIONS: Association of increased expression of miR-21 and better prognosis in the poor prognostic group may be of interest and could be explored in future prospective clinical trials.

Published
2022

8. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Author

Benavides M, Gomez-Espana A, Garcia-Alfonso P, Gonzalez C, Vieitez J, Rivera F, Safont M, Abad A, Sastre J, Valladares-Ayerbes M, Carrato A, Gonzalez-Flores E, Robles L, Salud A, Alonso-Orduna V, Montagut C, Asensio E, Diaz-Rubio E, and Aranda E

Subjects
Targeted therapy, Retrospective, Sidedness, Upfront primary tumour resection, Synchronous unresectable metastasis, RAS
Abstract

Introduction: Retrospective studies and meta-analyses suggest that upfront primary tumour resection (UPTR) confers a survival benefit in patients with asymptomatic unresectable metastatic colorectal cancer (mCRC) undergoing chemotherapy, however a consensus of its role in routine clinical practice in the current era of targeted therapies is lacking. This retrospective study aimed to analyse the survival benefit of UPTR in terms of tumour location and mutational status, in patients with synchronous mCRC receiving chemotherapy and targeted therapy. Patients and methods: Survival was analysed in a pooled cohort of synchronous mCRC patients treated with a first-line anti-VEGF or anti-EGFR inhibitor in seven trials of the Spanish TTD group, according to UPTR, tumour-sidedness and mutational profiling. Results: Of 1334 eligible patients, 642 (48%) had undergone UPTR. UPTR was associated with significantly longer overall survival (OS; 25.0 vs 20.3 months; HR 1.30, 95%CI 1.15-1.48; p < 0.0001). UPTR was associated with significant OS benefit in both left-sided (HR 1.38, 95%CI 1.13-1.69; p = 0.002) and right-sided (HR 1.39, 95%CI 1.00-1.94; p = 0.049) tumours, RASwt (HR 1.29, 95%CI 1.05-1.60; p = 0.016) and BRAFwt (HR 1.49, 95%CI 1.21-1.84; p = 0.0002) tumours, and treatment with anti-EGFRs (HR 1.47, 95%CI 1.13-1.92; p = 0.004) and anti-VEGFs (HR 1.25, 95%CI 1.08-1.44; p = 0.003). Multivariate analysis identified number of metastatic sites, RAS status, primary tumour location and UPTR as independent prognostic factors for OS. Conclusion: Considering the selection bias inherent to this study, our results support UPTR before first-line anti-EGFR or anti-VEGF targeted therapy in right and left-sided asymptomatic unresectable synchronous mCRC patients. RAS/BRAF mutational status may also influence UPTR function. (C) 2021 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Published
2022

9. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)

Author

Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Díaz-Pérez, J.A., Martínez del Prado, M.P., Alonso Orduña, V., Sevilla-García, I., Villabona-Artero, C., Beguiristain-Gómez, A., Llanos-Muñoz, M., Marazuela, M., Alvarez-Escola, C., Castellano, D., Vilar, E., Jiménez-Fonseca, P., Teulé, A., Sastre-Valera, J., Benavent-Viñuelas, M., Monleon, A., and Salazar, R.

Published
2010
Full Text
View/download PDF

10. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Author

Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, and Spanish Cooperative Grp Treatment

Abstract

Background Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective This study was undertaken to compare the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods This retrospective analysis used pooled data from five trials undertaken by the Spanish Cooperative Group for the Treatment of Digestive Tumours. All were studies of adults with advanced CRC who received first-line treatment with chemotherapy plus bevacizumab, cetuximab or panitumumab, stratified by age (>= 65 vs. < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results In total, 999 patients from five studies were included in the analysis: 480 (48%) were aged >= 65 years, and 519 (52%) were aged < 65 years. Median PFS did not differ significantly between patients aged >= 65 and < 65 years (9.9 vs. 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88-1.17). Median OS was significantly shorter in older than in younger patients (21.3 vs. 25.0 months; HR 1.21; 95% CI 1.04-1.41). There was no significant difference between older and younger patients in ORR (59 vs. 62%). Patients aged >= 65 years experienced significantly more treatment-related grade 3 or higher adverse events (61.67%) than did patients aged < 65 years (45.86%). Conclusions Biologicals plus chemotherapy is an effective first-line treatment option for selected patients aged >= 65 years with mCRC and has a manageable safety profile and efficacy comparable to that observed in younger patients.

Published
2021

11. 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort

Author

Oliveres, H., Alonso-Orduna, V., Feliu, J., Fernandez Montes, A., Martin-Richard, M., Galvez Munoz, E., Ruiz-Casado, A., Yubero Esteban, A., Aparicio, J., Alcaide-Garcia, J., Gallego Plazas, J., Carmona-Bayonas, A., Fernandez Martos, C., Gallego, M.R., Manzano Alemany, H., Leno, R., Esposito, F.M., Sapena, V., and Maurel, J.

Published
2023
Full Text
View/download PDF

12. Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results

Author

Salazar R, Capdevila J, Luis Manzano J, Pericay C, Martinez-Villacampa M, Lopez C, Losa F, Jose Safont M, Gomez-Espana A, Alonso-Orduna V, Escudero P, Gallego J, Garcia-Paredes B, Palacios A, Biondo S, Gravalos C, and Aranda E

Subjects
Bevacizumab, Chemoradiotherapy, Neoadjuvant, Locally-advanced rectal cancer
Abstract

BackgroundPreoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The "Tratamiento de Tumores Digestivos" group (TTD) previously reported in a randomized Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy endpoint (pathological complete response).We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at 3 and 5years.MethodsPatients (pts) were randomized to receive 5weeks of radiotherapy (45Gy/25 fractions) with concurrent Capecitabine 825mg/m2 twice daily, 5days per week with (arm A) or without (arm b) bevacizumab (5mg/kg once every 2weeks).ResultsIn our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4 and 76.2% vs 78.2% at 3 and 5years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%).Conclusionsthe addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or long term.Trial registrationEudraCT number: 2009-010192-24.Clinicaltrials.gov number: NCT01043484.

Published
2020

14. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings†

Author

Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D., Andel, J, Balcke, P, Benedicic, B, Eisterer, W, Fridrik, M, Jagdt, B, Keil, F, Kretschmer, A, Krippl, P, Oexle, H, Pecherstorfer, M, Samonigg, H, Schmid, M, Thaler, J, Tinchon, C, Weiss, H., Arts, J, De Man, M, Demolin, G, Janssens, J, Polus, M., Benczikova, B, Melichar, B, Prausova, J, Vitek, P., Andersen, FZ, Jensen, BB, Keldsen, N, Østerlind, K, Vistisen, K., Elme, A, Magi, A, Ojamaa, K., Ristamäki, R, Salminen, T., Ben Abdelghani, M, Bouche, O, Borg, C, Bouhier-Leporrier, K, Breysacher, G, Chone, L, Clavero Fabri, M-C, Deplanque, G, Desseigne, F, Dourthe, L-M, Ezenfis, J, Faroux, R, François, E, Garnier, C, Gaspard, M-H, Hebbar, M, Illory, JF, Kaminsky, M-C, Lecomte, T, Legoux, J-L, Levache, B, Lobry, C, Lotz, J-P, Mabro, M, Manet-Lacombe, S, Manfredi, S, Matysiak Budnik, T, Miglianico, L, Mineur, L, Moullet, I, Naman, H, Nouyrigat, P, Oziel-Taieb, S, Perrier, H, Pezet, D, Philip, J, Pottier, V, Porneuf, M, Ramdani, M, Re, D, Rinaldi, Y, Spaeth, D, Taieb, J, Terrebonne, E, Texereau, P, Thirot Bidault, A, Tournigand, C, Tubiana-Mathieu, N, Vantelon, J-M, Viret, F, Ychou, M., Bangerter, M, Bertram, ME, Bohnsteen, B, Brinkmann, L, Caca, K, Constantin, C, Cordes, H-J, Dietrich, G, Eggert, J, Engel, E, Fahlke, J, Fensterer, H, Florschütz, A, Folprecht, G, Forstbauer, H, Freier, W, Freund, M, Frickhofen, N, Gäbele, E, Geiler, M, Gieseler, F, Göhler, T, Graeven, U, Groschek, M, Grundeis, M, Hacker, U, Hagen, V, Hebart, HF, Hegewisch-Becker, S, Heike, M, Herrmann, T, Hildebrandt, B, Höffkes, H-G, Hübner, G, Hübner, J, Kettner, E, Kneba, M, Kohnke, JW, Kojouharoff, G, König, C, Kretzschmar, A, Kröning, H, Kürner, K, Lammert, F, Lerchenmüller, C, Lück, A, Meiler, J, Mergenthaler, H-G, Müller, L, Müller-Naendrup, C, Nusch, A, Papke, J, Porschen, R, Rädle, J, Reddemann, C, Ridwelski, K, Riera-Knorrenschild, J, Rudi, J, Schmalenberger, A, Schimanski, C-C, Schlegel, F, Schlichting, C, Schmidt, P, Schmiegel, W, Schmitz, S, Schulze-Bergkamen, H, Schwaner, I, Schwarzer, A, Schwerdtfeger, M, Selbach, J, Sieber, M, Siebler, J, Staib, P, Stauch, M, Steffens, C-C, Stübs, P, Tischendorf, J, Trarbach, T, Tummes, D, Valdix, A-R, Vogel, A, Von Wichert, GPL, Walther, M, Welslau, W, Wilhelm, G, Wobster, H, Wolf, T, Zeigenhagen, N, Zomorodbaksch, B., Batman, E, Bloemendal, HJ, Kehrer, DFS., Guren, T, Indrebø, G, Kersten, C, Soerbye, H., Fragoso, M, Fragoso, R, Mellidez, JC, Sa, A., Aljobran, A, Darwish, T., Alonso-Orduna, V, Aparicio, J, Aranda, E, Bosch, C, Galan-Brotons, A, Busquier Hernandez, I, Camara, JC, Campos Cervera, JM, Carlos Garcia Giron, C, Del Prado, PM, Donnay, O, Escudero, P, Falco, E, Gallego Plazas, J, Garcia Alfonso, P, Gonzalez Flores, E, Gravalos, C, Guardeno, R, Juárez, A, Lopez Ladron, A, Losa Gaspa, F, MVicent Vergé, J, Marcuello Gaspar, E, Massuti Sureda, B, Molina, J, Montero, IC, Muñoa, AL, Naranjo, MB, Oruezabal Moreno, MJ, Pachón Olmos, V, Pericay, C, Reina Zoilo, JJ, Rivera, F, Ruiz Casado, A, Safont, MJ, Salud Salvia, A, Tobena, M, Toral, JC, Valenti, V, Valladares Ayerbes, M, Vieitez, JM, Vera, R, Vieitez, JM., Berglund, A, Fernebro, E., Hess-Umbricht, V, Pless, M, Popescu, R, and Winterhalder, R.

Published
2013
Full Text
View/download PDF

15. 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE)

Author

Fonseca, P. Jimenez, primary, La Salvia, A., additional, Capdevila, J., additional, Castaño, A., additional, Benavent, M., additional, Alonso-Orduna, V., additional, Alonso, T., additional, Canovas, M. Sanchez, additional, Custodio, A., additional, Centeno, R. Garcia, additional, Llanos, M., additional, Crespo, G., additional, Lopez de Sa, A., additional, Teule, A., additional, Fernández, L. Oliva, additional, Torres, I., additional, Plazas, J. Gallego, additional, Pericay, C., additional, Villabona, C., additional, and López, C., additional

Published
2020
Full Text
View/download PDF

16. 1167P SILVELUL SCORE: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumours (PanNET) treated with everolimus or CAPTEM

Author

Viudez, A., primary, Crespo, G., additional, Gómez-Dorronsoro, M.L., additional, Custodio, A., additional, Benavent, M., additional, Paredes, B. García, additional, Hernando, J., additional, Alonso-Orduna, V., additional, Goñi, S., additional, López, C., additional, Jimenez-Fonseca, P., additional, González, I., additional, López-San Vicente, B., additional, García, I. Sevilla, additional, Hernandez, I., additional, Carmona, A., additional, Sanz, J. Pérez, additional, Ricarte, L. Lopez, additional, Marin, J., additional, and De Jesus-Acosta, A., additional

Published
2020
Full Text
View/download PDF

17. 474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC)

Author

Gomez, O. Higuera, primary, Soto, V. Heredia, additional, Machado, I., additional, Mendez, M.C., additional, Cuatrecasas, M., additional, Horndler, C., additional, Vermeulen, L., additional, Hoorn, S. Ten, additional, Mendiola, M., additional, Martín-Richard, M., additional, Ruiz-Casado, A., additional, Galvez, E., additional, Aparicio, J., additional, García, I. Sevilla, additional, Leno, R., additional, Fernández-Martos, C., additional, Alonso-Orduna, V., additional, Montes, A. Fernandez, additional, Maurel, J., additional, and Feliu, J., additional

Published
2020
Full Text
View/download PDF

18. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score

Author

Seguí, E., primary, Alonso-Orduna, V., additional, Sesma, A., additional, Martin-Richard, M., additional, Salud, A., additional, Fernández-Montes, A., additional, Fernández-Martos, C., additional, Ruiz-Casado, A., additional, Gallego, J., additional, Aparicio, J., additional, Gálvez, E., additional, Manzano, H., additional, Alcaide-Garcia, J., additional, Gallego, R., additional, Falco, E., additional, Esposito, F., additional, Oliveres, H., additional, Torres, F., additional, Feliu, J., additional, and Maurel, J., additional

Published
2020
Full Text
View/download PDF

19. P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study

Author

Santos Vivas, C., Salva, F., Fernández-Rodríguez, C., Alonso Orduña, V., Losa, F., Paez, D., Vidal, J., Salud, A., Ribera Fernández, P., Safont Aguilera, M., Tarazona, N., Hernández-Yagüe, X., Layos Romero, L., Garcia-Carbonero, R., Rivera, F., Álvarez Gallego, R., Bellosillo, B., and Montagut, C.

Published
2022
Full Text
View/download PDF

21. P-69 Anal squamous cell carcinoma (ASCC) outcomes in clinical practice: From localized to metastatic setting

Author

Esteban Villarrubia, J., Hernando, J., Gómez Mugarza, P., García Álvarez, A., Torres Jiménez, J., Orejana Martín, I., Alonso Orduña, V., Gómez-Puerto, D., Álvarez Ballesteros, P., Polo, E., López, D., Martínez Delfrade, Í., López Roldán, B., Roca, M., Reguera Puertas, P., Barriendos Sanz, S., Benini, L., Ferreiro Monteagudo, R., Monreal Cepero, M., Campos Ramírez, S., Guillén-Ponce, C., and Capdevila, J.

Published
2022
Full Text
View/download PDF

22. Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Author

Barrull, J Vidal, primary, Casadevall, D., additional, Fernandez, M.C., additional, Castro-Henriques, M., additional, García-Alfonso, P., additional, Martin-Cullell, B., additional, Alonso-Orduna, V., additional, Alonso, R M Rodríguez, additional, Benavides, M., additional, Vivas, C Santos, additional, Fernández, E Elez, additional, Garcia-Carbonero, R., additional, Ferreiro, R., additional, Manzano, J.L., additional, Losa, F., additional, Salazar, R., additional, Tabernero, J., additional, Aguilar, E Aranda, additional, Bellosillo, B., additional, and Viladot, C Montagut, additional

Published
2019
Full Text
View/download PDF

23. P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study

Author

García-Alfonso, P., Reina Zoilo, J., Mata Velasco, E., Llanos, M., Illán Varella, A., Safont Aguilera, M., Delgado Ureña, M., Castañón, C., Pimentel, P., Alonso Orduña, V., Mendez, J., Rivera Herrero, F., Siso, I., Rodriguez-Pascual, J., Grávalos Castro, C., Afonso, R., Fernandez Rañada, I., Grández, R., Moreno, M., López Muñoz, A., García-Paredes, B., and Aranda, E.

Published
2021
Full Text
View/download PDF

24. P-245 GETNET-SILVELUL study: An original or modified immunohistochemical score (IPS or mIPS) in patients (pts) with pancreatic neuroendocrine tumors (PanNET) treated with everolimus or CAPTEM

Author

Viudez, A., Crespo, G., Dorronsoro, M. Gomez, Paredes, B. García, Custodio, A., Hernando, J., Sevilla, I., Goñi, S., Lopez, C., Benavent, M., Fonseca, P. Jimenez, Alonso-Orduña, V., Borja, I. González, Hernandez, I., Muñoz, M. Llanos, Carmona, A., Sanz, J. Pérez, Vicente, B. Lopez-San, and Jesus-Acosta, A. De

Published
2020
Full Text
View/download PDF

25. 625P - Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Author

Barrull, J Vidal, Casadevall, D., Fernandez, M.C., Castro-Henriques, M., García-Alfonso, P., Martin-Cullell, B., Alonso-Orduna, V., Alonso, R M Rodríguez, Benavides, M., Vivas, C Santos, Fernández, E Elez, Garcia-Carbonero, R., Ferreiro, R., Manzano, J.L., Losa, F., Salazar, R., Tabernero, J., Aguilar, E Aranda, Bellosillo, B., and Viladot, C Montagut

Published
2019
Full Text
View/download PDF

26. A Validation of Current Prognostic Scores in Metastatic Colorectal Cancer (Mcrc) and a New Prognostic Score (A Gemcad Study)

Author

Alonso-Orduna, V., primary, Marmol, M., additional, Escudero, P., additional, Salud, A., additional, Safont, M.J., additional, Méndez, J.C., additional, Girón, C. García, additional, Martín, M., additional, Fernandez-Martos, C., additional, Albéniz, X. García, additional, Feliu, J., additional, and Maurel, J., additional

Published
2014
Full Text
View/download PDF

27. Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with First-Line BEV + CT (ML18147): Efficacy and Safety Analyses by Oxaliplatin vs Irinotecan-Based CT

Author

Österlund, P., primary, Alonso-Orduna, V., additional, Schlichting, C., additional, André, T., additional, Sastre, J., additional, Greil, R., additional, Kubicka, S., additional, Reyes-Rivera, I., additional, McCall, B., additional, and Van Cutsem, E.J.D., additional

Published
2012
Full Text
View/download PDF

28. 1147P - Everolimus (Eve) Treatment for Advanced G1-G2 Neuroendocrine Tumours (Nets) in the Community Setting: Clinical Benefit Irrespective of Grade or Primary Tumour Site

Author

Custodio, Jimenez Fonseca, P., Alonso-Orduna, V., López, C., Alonso Gordoa, T., Crespo, G., Carmona-Bayonas, A., Álvarez-Escolá, C., Polo, E., Mangas, M., Herrera Gómez, R.G., Solís Hernández, M.D.P., Jimeno, R., Reguera, P., Ayuela, S., Madero, R., Burgos, E., Grande, E., Feliu, J., and Barriuso, J.

Published
2014
Full Text
View/download PDF

31. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Author

Marta Martin-Richard, Joan Maurel, Jaime Feliu, Teresa Fernandez, Maria Elena Sanchez, Isabel Sevilla, Jaume Capdevila, Ana Leon, Rocio Garcia-Carbonero, Miriam López-Gómez, Ismael Ghanem, Vicente Alonso-Orduña, Laura Cerezo, Carmen Castanon, Pilar García-Alfonso, Monica Caro, Inmaculada Guasch, Begona Quintana-Angel, Carles Conill, Carlos F. Lopez, Amgen, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ), Institut Català de la Salut, [Feliu J] Department of Medical Oncology, CIBERONC, Catedra UAM-AMGEN, Hospital Universitario La Paz, Madrid, Spain. [Garcia-Carbonero R] Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain. Department of Medical Oncology, imas12, UCM, CNIO, CIBERONC, Hospital Universitario 12 de Octubre, Madrid, Spain. [Capdevila J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Guasch I] Department of Medical Oncology, Hospital Althaia-Manresa, Manresa, Spain. [Alonso-Orduna V] Department of Medical Oncology, Instituto de Investigacion Sanitaria de Aragon, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Lopez C] Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Cancer Research, Colorectal cancer, medicine.medical_treatment, Phases of clinical research, chemotherapy, Severity of Illness Index, Gastroenterology, Target therapy, Recte - Càncer - Quimioteràpia, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto::neoplasias del ano [ENFERMEDADES], neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma de células escamosas [ENFERMEDADES], Rectal cancer, Original Research, Aged, 80 and over, Proctectomy, Panitumumab, Middle Aged, Anal canal, Anus Neoplasms, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Recte - Càncer - Radioteràpia, Primary tumor, Neoadjuvant Therapy, Survival Rate, medicine.anatomical_structure, Oncology, terapéutica::tratamiento combinado::quimiorradioterapia::quimiorradioterapia complementaria [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], 030220 oncology & carcinogenesis, Female, Fluorouracil, Radiodermatitis, medicine.drug, Adult, medicine.medical_specialty, Neutropenia, Medicina, Mitomycin, lcsh:RC254-282, Disease-Free Survival, 03 medical and health sciences, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms::Anus Neoplasms [DISEASES], Internal medicine, medicine, Humans, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Squamous Cell [DISEASES], Chemotherapy, Radiology, Nuclear Medicine and imaging, rectal cancer, radiotherapy, Aged, Radiotherapy, target therapy, business.industry, Therapeutics::Combined Modality Therapy::Chemoradiotherapy::Chemoradiotherapy, Adjuvant [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Clinical Cancer Research, Chemoradiotherapy, Adjuvant, medicine.disease, Radiation therapy, Regimen, 030104 developmental biology, business, Follow-Up Studies
Abstract

Aim VITAL, a phase II single‐arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). Methods Adult, treatment‐naïve SCCAC patients (Stage T2‐T4, any N, M0) and ECOG‐PS ≤2, received panitumumab (6 mg/kg, day 1 and Q2W; 8 weeks), 5‐FU (1000 mg/m2/d, days 1‐4 and 29‐32), MMC (10 mg/m2, days 1 and 29) and RT 45 Gy (1.8 Gy/fraction) to the primary tumor and mesorectal, iliac and inguinal lymph nodes, plus 10‐15 Gy boost dose to the primary tumor and affected lymph nodes. The primary objective was disease free survival rate (DFS) at 3‐years (expected 3‐year DFS rate: 73.7 ± 12%). Results Fifty‐eight patients (31 women; median age: 59 years; ECOG‐PS 0‐1:98%; TNM II [29%] (T2 or T3/N0/M0)/IIIA (T1‐T3/N1/M0 or T4/N0/M0) [21%]/IIIB (T4/N1/M0 or any T/N2 or N3/M0) [47%]/nonevaluable [4%]) were included. The median follow‐up was 45 months. The 3‐year DFS rate was 61.1% (95% CI: 47.1, 72.4). The 3‐year overall survival rate was 78.4% (95% CI: 65.1, 87.1). Eighteen patients (31.0%) required a colostomy within 2 years posttreatment. Grade 3‐4 toxicities were experienced by 53 (91%) patients. Most common grade 3‐4 treatment‐related events were radiation skin injury (40%) and neutropenia (24%). No toxic deaths occurred. Improved efficacy in colostomy‐free survival and complete response rate was observed in human papilloma virus positive patients. Conclusions Panitumumab addition to MMC‐5FU regimen in SCCAC patients increases toxicity and does not improve patients’ outcomes. RT plus MMC‐5FU remains the standard of care for localized SCCAC patients., VITAL, a phase II single‐arm study, was aimed to evaluate efficacy and safety of panitumumab addition to 5‐fluorouracil (5‐FU), mitomycin‐C (MMC) and radiotherapy in patients with localized squamous cell carcinoma of the anal canal (SCCAC). The study concluded that panitumumab addition to MMC‐5FU regimen in SCCAC patients increases toxicity and does not improve patients’ outcomes.

Published
2020

32. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).

Author

Feliu J, Garcia-Carbonero R, Capdevila J, Guasch I, Alonso-Orduna V, Lopez C, Garcia-Alfonso P, Castanon C, Sevilla I, Cerezo L, Conill C, Quintana-Angel B, Sanchez ME, Ghanem I, Martin-Richard M, Lopez-Gomez M, Leon A, Caro M, Fernandez T, and Maurel J

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Anus Neoplasms mortality, Chemoradiotherapy, Adjuvant methods, Disease-Free Survival, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Follow-Up Studies, Humans, Male, Middle Aged, Mitomycin administration & dosage, Mitomycin adverse effects, Neoadjuvant Therapy methods, Neutropenia diagnosis, Neutropenia etiology, Panitumumab administration & dosage, Panitumumab adverse effects, Proctectomy, Radiodermatitis diagnosis, Radiodermatitis etiology, Severity of Illness Index, Survival Rate, Antineoplastic Combined Chemotherapy Protocols adverse effects, Anus Neoplasms therapy, Chemoradiotherapy, Adjuvant adverse effects, Neoadjuvant Therapy adverse effects, Neutropenia epidemiology, Radiodermatitis epidemiology
Abstract

Aim: VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC)., Methods: Adult, treatment-naïve SCCAC patients (Stage T2-T4, any N, M0) and ECOG-PS ≤2, received panitumumab (6 mg/kg, day 1 and Q2W; 8 weeks), 5-FU (1000 mg/m 2 /d, days 1-4 and 29-32), MMC (10 mg/m 2 , days 1 and 29) and RT 45 Gy (1.8 Gy/fraction) to the primary tumor and mesorectal, iliac and inguinal lymph nodes, plus 10-15 Gy boost dose to the primary tumor and affected lymph nodes. The primary objective was disease free survival rate (DFS) at 3-years (expected 3-year DFS rate: 73.7 ± 12%)., Results: Fifty-eight patients (31 women; median age: 59 years; ECOG-PS 0-1:98%; TNM II [29%] (T2 or T3/N0/M0)/IIIA (T1-T3/N1/M0 or T4/N0/M0) [21%]/IIIB (T4/N1/M0 or any T/N2 or N3/M0) [47%]/nonevaluable [4%]) were included. The median follow-up was 45 months. The 3-year DFS rate was 61.1% (95% CI: 47.1, 72.4). The 3-year overall survival rate was 78.4% (95% CI: 65.1, 87.1). Eighteen patients (31.0%) required a colostomy within 2 years posttreatment. Grade 3-4 toxicities were experienced by 53 (91%) patients. Most common grade 3-4 treatment-related events were radiation skin injury (40%) and neutropenia (24%). No toxic deaths occurred. Improved efficacy in colostomy-free survival and complete response rate was observed in human papilloma virus positive patients., Conclusions: Panitumumab addition to MMC-5FU regimen in SCCAC patients increases toxicity and does not improve patients' outcomes. RT plus MMC-5FU remains the standard of care for localized SCCAC patients., (© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results